Madrigal Pharmaceuticals Inc
1MDGL
Company Profile
Business description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Contact
200 Barr Harbor Drive
Suite 200, Four Tower Bridge
West ConshohockenPA19428
USAT: +1 267 824-2827
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,571.40 | 40.30 | -0.47% |
CAC 40 | 7,864.44 | 46.05 | -0.58% |
DAX 40 | 23,999.17 | 123.23 | -0.51% |
Dow JONES (US) | 42,038.68 | 178.24 | 0.43% |
FTSE 100 | 8,739.26 | 47.20 | -0.54% |
HKSE | 23,544.31 | 283.47 | -1.19% |
NASDAQ | 19,036.52 | 163.87 | 0.87% |
Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
S&P 500 | 5,871.01 | 26.40 | 0.45% |
S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
SSE Composite Index | 3,380.19 | 7.39 | -0.22% |